Osilodrostat phosphate Chiral

About Osilodrostat phosphate Chiral

Osilodrostat phosphate is a chiral active pharmaceutical ingredient (API) used primarily for the treatment of Cushing's disease, where it acts as a potent inhibitor of adrenal steroidogenesis by blocking the enzyme 11-hydroxylase (CYP11B1), thereby reducing cortisol production. The molecule contains stereogenic center(s), making chirality crucial for its pharmacological activity, selectivity, and safety profile. It is also known by the synonym osilodrostat (INN) and is marketed under the brand name Isturisa. Industrially, osilodrostat phosphate is significant in the pharmaceutical manufacturing sector, where it is produced through enantioselective synthesis or chiral resolution techniques to ensure high enantiomeric purity; it is further formulated into oral dosage forms for endocrine therapy. Additionally, it is used in process development and chiral chemistry research as a model compound for optimizing asymmetric synthesis and scale-up of steroidogenesis inhibitors.